title: [Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case].
abstract: Long-term users of tamoxifen (TMX) are at increased risk for developing endometrial cancer. Early diagnosis is mainly based on transvaginal scan (TVS) and hysteroscopy with endometrial biopsy. Nevertheless, TVS does not provide a definitive diagnosis in most cases, particularly due to its high false-positive rate. In addition TMX related changes, such as "pseudocistic" pattern, affect endoscopic evaluation of the endometrium and biopsy sampling (in particular blind procedures) frequently yields insufficient tissue for diagnosis. The cause of the high inadequacy rate of endometrial biopsies in women on TMX might be related to the increase in endometrial fibrous component. The present case emphasizes the main difficulties in surveillance and early diagnosis of endometrial pathologies in TMX users. Liquid-based endometrial cytology played a determinant role in the diagnostic pathway of this patient. We believe it could be used solely or in association with TVS leading to many advantages in the surveillance of women receiving TMX.
authors.affiliation: Dipartimento di Scienze per la Salute della Donna e del Bambino, Sezione di Ginecologia ed Ostetricia, Università degli Studi di Firenze, Italia. maxfambrini@libero.it
authors.forename: M
authors.initials: M
authors.lastname: Fambrini
authors.forename: A M
authors.initials: AM
authors.lastname: Buccoliero
authors.forename: A
authors.initials: A
authors.lastname: Pieralli
authors.forename: K L
authors.initials: KL
authors.lastname: Andersson
authors.forename: A
authors.initials: A
authors.lastname: Mattei
authors.forename: G
authors.initials: G
authors.lastname: Scarselli
authors.forename: G
authors.initials: G
authors.lastname: Taddei
authors.forename: M
authors.initials: M
authors.lastname: Marchionni
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy*; D003581:Cytodiagnosis / Q000379:methods; D003937:Diagnosis, Differential; D055088:Early Detection of Cancer; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D015907:Hysteroscopy / Q000379:methods; D008408:Mastectomy; D017698:Postmenopause; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen